Mishra, Ila https://orcid.org/0000-0002-9786-6358
Feng, Bing https://orcid.org/0000-0002-7403-8402
Basu, Bijoya https://orcid.org/0000-0001-5122-9807
Brown, Amanda M.
Kim, Linda H. https://orcid.org/0000-0003-0628-3104
Lin, Tao https://orcid.org/0000-0002-6441-067X
Raza, Mir Abbas https://orcid.org/0009-0002-9897-7372
Moore, Amelia
Hahn, Abigayle
Bailey, Samantha
Sharp, Alaina
Bournat, Juan C.
Poulton, Claire
Kim, Brian
Langsner, Amos
Sathyanesan, Aaron https://orcid.org/0000-0002-9226-7831
Sillitoe, Roy V. https://orcid.org/0000-0002-6177-6190
He, Yanlin https://orcid.org/0000-0002-5471-9016
Chopra, Atul R. https://orcid.org/0000-0002-1304-3777
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK130931)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK125403)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK118290)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK102529)
Article History
Received: 9 May 2023
Accepted: 7 June 2024
First Online: 10 July 2024
Competing interests
: A.R.C. has been awarded asprosin-related patents and is a co-founder and equity holder of Aceragen and Recall Therapeutics. The other authors declare no competing interests.